nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—breast cancer—ovarian cancer	0.376	1	CtDrD
Tamoxifen—CYP1B1—ovarian cancer	0.107	0.51	CbGaD
Tamoxifen—DHCR7—Epirubicin—ovarian cancer	0.0764	0.282	CbGbCtD
Tamoxifen—ESR1—ovarian cancer	0.0719	0.344	CbGaD
Tamoxifen—DHCR7—Doxorubicin—ovarian cancer	0.0406	0.15	CbGbCtD
Tamoxifen—ABCB1—ovarian cancer	0.0306	0.146	CbGaD
Tamoxifen—CYP1B1—Paclitaxel—ovarian cancer	0.0119	0.044	CbGbCtD
Tamoxifen—ABCB11—Paclitaxel—ovarian cancer	0.0119	0.044	CbGbCtD
Tamoxifen—ABCG2—Topotecan—ovarian cancer	0.0115	0.0422	CbGbCtD
Tamoxifen—CYP19A1—Paclitaxel—ovarian cancer	0.00968	0.0357	CbGbCtD
Tamoxifen—CYP1B1—Docetaxel—ovarian cancer	0.00863	0.0318	CbGbCtD
Tamoxifen—CYP1B1—Doxorubicin—ovarian cancer	0.00644	0.0237	CbGbCtD
Tamoxifen—ABCB11—Doxorubicin—ovarian cancer	0.00644	0.0237	CbGbCtD
Tamoxifen—ABCC2—Paclitaxel—ovarian cancer	0.00628	0.0231	CbGbCtD
Tamoxifen—ABCC2—Carboplatin—ovarian cancer	0.00591	0.0218	CbGbCtD
Tamoxifen—ABCG2—Paclitaxel—ovarian cancer	0.00568	0.0209	CbGbCtD
Tamoxifen—ABCG2—Carboplatin—ovarian cancer	0.00534	0.0197	CbGbCtD
Tamoxifen—ABCC2—Docetaxel—ovarian cancer	0.00454	0.0167	CbGbCtD
Tamoxifen—CYP3A7—Paclitaxel—ovarian cancer	0.00419	0.0154	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.00419	0.0154	CbGbCtD
Tamoxifen—ABCB1—Topotecan—ovarian cancer	0.00414	0.0152	CbGbCtD
Tamoxifen—ABCG2—Docetaxel—ovarian cancer	0.0041	0.0151	CbGbCtD
Tamoxifen—CYP19A1—follicular fluid—ovarian cancer	0.0038	0.0979	CbGeAlD
Tamoxifen—ABCC2—Doxorubicin—ovarian cancer	0.00338	0.0125	CbGbCtD
Tamoxifen—CYP3A5—Paclitaxel—ovarian cancer	0.00315	0.0116	CbGbCtD
Tamoxifen—ABCG2—Doxorubicin—ovarian cancer	0.00306	0.0113	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.00303	0.0112	CbGbCtD
Tamoxifen—CYP3A7—Docetaxel—ovarian cancer	0.00303	0.0112	CbGbCtD
Tamoxifen—CYP2C8—Paclitaxel—ovarian cancer	0.00302	0.0111	CbGbCtD
Tamoxifen—ABCB1—Vinorelbine—ovarian cancer	0.00291	0.0107	CbGbCtD
Tamoxifen—CYP2D6—Vinorelbine—ovarian cancer	0.00275	0.0101	CbGbCtD
Tamoxifen—CYP3A4—Topotecan—ovarian cancer	0.00248	0.00913	CbGbCtD
Tamoxifen—CYP3A5—Docetaxel—ovarian cancer	0.00227	0.00838	CbGbCtD
Tamoxifen—CYP19A1—corpus luteum—ovarian cancer	0.00219	0.0564	CbGeAlD
Tamoxifen—ESR2—ovarian follicle—ovarian cancer	0.00217	0.056	CbGeAlD
Tamoxifen—CYP2B6—Doxorubicin—ovarian cancer	0.00215	0.00793	CbGbCtD
Tamoxifen—CYP2C9—Paclitaxel—ovarian cancer	0.00211	0.00777	CbGbCtD
Tamoxifen—ABCB1—Paclitaxel—ovarian cancer	0.00205	0.00754	CbGbCtD
Tamoxifen—CYP3A4—Vinorelbine—ovarian cancer	0.00175	0.00643	CbGbCtD
Tamoxifen—CYP19A1—ovarian follicle—ovarian cancer	0.00171	0.0441	CbGeAlD
Tamoxifen—ESR1—ovarian follicle—ovarian cancer	0.00149	0.0383	CbGeAlD
Tamoxifen—ABCB1—Docetaxel—ovarian cancer	0.00148	0.00545	CbGbCtD
Tamoxifen—CYP3A4—Paclitaxel—ovarian cancer	0.00123	0.00452	CbGbCtD
Tamoxifen—ABCB1—Doxorubicin—ovarian cancer	0.0011	0.00406	CbGbCtD
Tamoxifen—CYP2D6—Doxorubicin—ovarian cancer	0.00104	0.00383	CbGbCtD
Tamoxifen—ESR2—oviduct—ovarian cancer	0.000955	0.0246	CbGeAlD
Tamoxifen—CYP3A4—Docetaxel—ovarian cancer	0.000887	0.00327	CbGbCtD
Tamoxifen—EBPL—epithelium—ovarian cancer	0.000718	0.0185	CbGeAlD
Tamoxifen—EBP—uterine cervix—ovarian cancer	0.000683	0.0176	CbGeAlD
Tamoxifen—CYP3A4—Doxorubicin—ovarian cancer	0.000661	0.00244	CbGbCtD
Tamoxifen—ESR1—oviduct—ovarian cancer	0.000654	0.0168	CbGeAlD
Tamoxifen—EBP—uterus—ovarian cancer	0.000569	0.0147	CbGeAlD
Tamoxifen—EBP—female reproductive system—ovarian cancer	0.000511	0.0132	CbGeAlD
Tamoxifen—ESRRA—myometrium—ovarian cancer	0.000509	0.0131	CbGeAlD
Tamoxifen—EBPL—female gonad—ovarian cancer	0.000485	0.0125	CbGeAlD
Tamoxifen—EBPL—testis—ovarian cancer	0.000431	0.0111	CbGeAlD
Tamoxifen—SULT1A1—female reproductive system—ovarian cancer	0.000424	0.0109	CbGeAlD
Tamoxifen—DHCR7—uterine cervix—ovarian cancer	0.000402	0.0104	CbGeAlD
Tamoxifen—FMO1—uterine cervix—ovarian cancer	0.000402	0.0104	CbGeAlD
Tamoxifen—ESRRA—uterine cervix—ovarian cancer	0.000396	0.0102	CbGeAlD
Tamoxifen—SULT1A1—female gonad—ovarian cancer	0.000386	0.00994	CbGeAlD
Tamoxifen—SULT1A1—vagina—ovarian cancer	0.000383	0.00988	CbGeAlD
Tamoxifen—ESRRA—decidua—ovarian cancer	0.000377	0.00972	CbGeAlD
Tamoxifen—FMO1—endometrium—ovarian cancer	0.000364	0.00938	CbGeAlD
Tamoxifen—ESRRA—endometrium—ovarian cancer	0.000358	0.00923	CbGeAlD
Tamoxifen—SULT1A1—testis—ovarian cancer	0.000342	0.00881	CbGeAlD
Tamoxifen—DHCR7—gonad—ovarian cancer	0.000338	0.0087	CbGeAlD
Tamoxifen—ESRRA—uterus—ovarian cancer	0.00033	0.0085	CbGeAlD
Tamoxifen—EBPL—lymph node—ovarian cancer	0.000312	0.00804	CbGeAlD
Tamoxifen—DHCR7—female reproductive system—ovarian cancer	0.000301	0.00777	CbGeAlD
Tamoxifen—ESRRA—female reproductive system—ovarian cancer	0.000297	0.00765	CbGeAlD
Tamoxifen—DHCR7—bone marrow—ovarian cancer	0.000285	0.00733	CbGeAlD
Tamoxifen—ESRRA—bone marrow—ovarian cancer	0.00028	0.00722	CbGeAlD
Tamoxifen—DHCR7—female gonad—ovarian cancer	0.000274	0.00707	CbGeAlD
Tamoxifen—FMO1—female gonad—ovarian cancer	0.000274	0.00707	CbGeAlD
Tamoxifen—DHCR7—vagina—ovarian cancer	0.000273	0.00702	CbGeAlD
Tamoxifen—FMO1—vagina—ovarian cancer	0.000273	0.00702	CbGeAlD
Tamoxifen—ESRRA—female gonad—ovarian cancer	0.00027	0.00696	CbGeAlD
Tamoxifen—ESRRA—vagina—ovarian cancer	0.000268	0.00691	CbGeAlD
Tamoxifen—SULT1A1—lymph node—ovarian cancer	0.000248	0.00639	CbGeAlD
Tamoxifen—DHCR7—testis—ovarian cancer	0.000243	0.00627	CbGeAlD
Tamoxifen—ESR2—epithelium—ovarian cancer	0.00024	0.00618	CbGeAlD
Tamoxifen—ESRRA—testis—ovarian cancer	0.000239	0.00617	CbGeAlD
Tamoxifen—ESR2—uterine cervix—ovarian cancer	0.000238	0.00612	CbGeAlD
Tamoxifen—SIGMAR1—myometrium—ovarian cancer	0.000237	0.0061	CbGeAlD
Tamoxifen—FMO3—vagina—ovarian cancer	0.000236	0.00607	CbGeAlD
Tamoxifen—ESR2—endometrium—ovarian cancer	0.000215	0.00554	CbGeAlD
Tamoxifen—ABCB11—testis—ovarian cancer	0.000213	0.00548	CbGeAlD
Tamoxifen—FMO3—testis—ovarian cancer	0.00021	0.00542	CbGeAlD
Tamoxifen—ESR1—myometrium—ovarian cancer	0.000209	0.00539	CbGeAlD
Tamoxifen—Diethylstilbestrol—ESR1—ovarian cancer	0.000208	0.207	CrCbGaD
Tamoxifen—CES1—female reproductive system—ovarian cancer	0.000206	0.0053	CbGeAlD
Tamoxifen—Ospemifene—ESR1—ovarian cancer	0.000202	0.202	CrCbGaD
Tamoxifen—ESR1—embryo—ovarian cancer	0.000201	0.00518	CbGeAlD
Tamoxifen—ESR2—gonad—ovarian cancer	0.000199	0.00514	CbGeAlD
Tamoxifen—ESR2—uterus—ovarian cancer	0.000198	0.0051	CbGeAlD
Tamoxifen—CES1—female gonad—ovarian cancer	0.000187	0.00482	CbGeAlD
Tamoxifen—SIGMAR1—uterine cervix—ovarian cancer	0.000184	0.00475	CbGeAlD
Tamoxifen—ESR2—female reproductive system—ovarian cancer	0.000178	0.00459	CbGeAlD
Tamoxifen—DHCR7—lymph node—ovarian cancer	0.000176	0.00454	CbGeAlD
Tamoxifen—FMO1—lymph node—ovarian cancer	0.000176	0.00454	CbGeAlD
Tamoxifen—SIGMAR1—decidua—ovarian cancer	0.000175	0.00452	CbGeAlD
Tamoxifen—ESRRA—lymph node—ovarian cancer	0.000174	0.00447	CbGeAlD
Tamoxifen—CYP19A1—endometrium—ovarian cancer	0.000169	0.00437	CbGeAlD
Tamoxifen—ABCG2—myometrium—ovarian cancer	0.000168	0.00432	CbGeAlD
Tamoxifen—CYP1B1—decidua—ovarian cancer	0.000167	0.0043	CbGeAlD
Tamoxifen—SIGMAR1—endometrium—ovarian cancer	0.000167	0.00429	CbGeAlD
Tamoxifen—CES1—testis—ovarian cancer	0.000166	0.00428	CbGeAlD
Tamoxifen—Toremifene—ESR1—ovarian cancer	0.000165	0.164	CrCbGaD
Tamoxifen—ESR1—epithelium—ovarian cancer	0.000164	0.00423	CbGeAlD
Tamoxifen—ESR1—uterine cervix—ovarian cancer	0.000163	0.00419	CbGeAlD
Tamoxifen—ESR2—female gonad—ovarian cancer	0.000162	0.00418	CbGeAlD
Tamoxifen—CYP2A6—vagina—ovarian cancer	0.000162	0.00417	CbGeAlD
Tamoxifen—ESR2—vagina—ovarian cancer	0.000161	0.00415	CbGeAlD
Tamoxifen—CYP19A1—gonad—ovarian cancer	0.000157	0.00405	CbGeAlD
Tamoxifen—CYP19A1—uterus—ovarian cancer	0.000156	0.00402	CbGeAlD
Tamoxifen—ESR1—decidua—ovarian cancer	0.000155	0.004	CbGeAlD
Tamoxifen—SIGMAR1—uterus—ovarian cancer	0.000153	0.00395	CbGeAlD
Tamoxifen—FMO3—lymph node—ovarian cancer	0.000152	0.00393	CbGeAlD
Tamoxifen—ESR1—endometrium—ovarian cancer	0.000147	0.00379	CbGeAlD
Tamoxifen—CYP1B1—gonad—ovarian cancer	0.000147	0.00379	CbGeAlD
Tamoxifen—CYP1B1—uterus—ovarian cancer	0.000146	0.00376	CbGeAlD
Tamoxifen—ESR2—testis—ovarian cancer	0.000144	0.0037	CbGeAlD
Tamoxifen—Clomifene—ESR1—ovarian cancer	0.000142	0.142	CrCbGaD
Tamoxifen—CYP19A1—female reproductive system—ovarian cancer	0.00014	0.00362	CbGeAlD
Tamoxifen—ESR1—gonad—ovarian cancer	0.000137	0.00352	CbGeAlD
Tamoxifen—ESR1—uterus—ovarian cancer	0.000136	0.0035	CbGeAlD
Tamoxifen—ABCC2—female reproductive system—ovarian cancer	0.000134	0.00345	CbGeAlD
Tamoxifen—CYP1B1—female reproductive system—ovarian cancer	0.000131	0.00338	CbGeAlD
Tamoxifen—ABCG2—uterine cervix—ovarian cancer	0.00013	0.00336	CbGeAlD
Tamoxifen—SIGMAR1—bone marrow—ovarian cancer	0.00013	0.00336	CbGeAlD
Tamoxifen—CYP19A1—female gonad—ovarian cancer	0.000128	0.00329	CbGeAlD
Tamoxifen—SIGMAR1—female gonad—ovarian cancer	0.000126	0.00324	CbGeAlD
Tamoxifen—CYP1A1—epithelium—ovarian cancer	0.000125	0.00322	CbGeAlD
Tamoxifen—SIGMAR1—vagina—ovarian cancer	0.000125	0.00322	CbGeAlD
Tamoxifen—ABCG2—decidua—ovarian cancer	0.000124	0.0032	CbGeAlD
Tamoxifen—CYP1A1—uterine cervix—ovarian cancer	0.000124	0.00319	CbGeAlD
Tamoxifen—ESR1—female reproductive system—ovarian cancer	0.000122	0.00314	CbGeAlD
Tamoxifen—CYP2C8—endometrium—ovarian cancer	0.000121	0.00313	CbGeAlD
Tamoxifen—CYP3A5—uterine cervix—ovarian cancer	0.000121	0.00312	CbGeAlD
Tamoxifen—CES1—lymph node—ovarian cancer	0.00012	0.0031	CbGeAlD
Tamoxifen—CYP1B1—female gonad—ovarian cancer	0.000119	0.00308	CbGeAlD
Tamoxifen—ABCG2—endometrium—ovarian cancer	0.000118	0.00304	CbGeAlD
Tamoxifen—CYP19A1—testis—ovarian cancer	0.000113	0.00292	CbGeAlD
Tamoxifen—SIGMAR1—testis—ovarian cancer	0.000111	0.00287	CbGeAlD
Tamoxifen—ESR1—female gonad—ovarian cancer	0.000111	0.00286	CbGeAlD
Tamoxifen—ESR1—vagina—ovarian cancer	0.00011	0.00284	CbGeAlD
Tamoxifen—ABCG2—uterus—ovarian cancer	0.000109	0.0028	CbGeAlD
Tamoxifen—ABCC2—testis—ovarian cancer	0.000108	0.00279	CbGeAlD
Tamoxifen—CYP1B1—testis—ovarian cancer	0.000106	0.00273	CbGeAlD
Tamoxifen—ESR2—lymph node—ovarian cancer	0.000104	0.00268	CbGeAlD
Tamoxifen—CYP2C19—vagina—ovarian cancer	0.000104	0.00268	CbGeAlD
Tamoxifen—CYP1A1—uterus—ovarian cancer	0.000103	0.00266	CbGeAlD
Tamoxifen—CYP2B6—gonad—ovarian cancer	0.000101	0.0026	CbGeAlD
Tamoxifen—CYP2C8—female reproductive system—ovarian cancer	0.0001	0.00259	CbGeAlD
Tamoxifen—ESR1—testis—ovarian cancer	9.84e-05	0.00254	CbGeAlD
Tamoxifen—CYP1A1—female reproductive system—ovarian cancer	9.28e-05	0.00239	CbGeAlD
Tamoxifen—ABCG2—bone marrow—ovarian cancer	9.22e-05	0.00238	CbGeAlD
Tamoxifen—CYP2C8—vagina—ovarian cancer	9.09e-05	0.00234	CbGeAlD
Tamoxifen—CYP2B6—female reproductive system—ovarian cancer	9.01e-05	0.00232	CbGeAlD
Tamoxifen—CYP2C9—female reproductive system—ovarian cancer	8.93e-05	0.0023	CbGeAlD
Tamoxifen—ABCG2—female gonad—ovarian cancer	8.89e-05	0.00229	CbGeAlD
Tamoxifen—ABCG2—vagina—ovarian cancer	8.84e-05	0.00228	CbGeAlD
Tamoxifen—Diethylstilbestrol—ABCB1—ovarian cancer	8.82e-05	0.0881	CrCbGaD
Tamoxifen—CYP2E1—female reproductive system—ovarian cancer	8.46e-05	0.00218	CbGeAlD
Tamoxifen—CYP1A1—female gonad—ovarian cancer	8.44e-05	0.00217	CbGeAlD
Tamoxifen—CYP1A1—vagina—ovarian cancer	8.39e-05	0.00216	CbGeAlD
Tamoxifen—ABCB1—myometrium—ovarian cancer	8.26e-05	0.00213	CbGeAlD
Tamoxifen—CYP3A5—female gonad—ovarian cancer	8.25e-05	0.00213	CbGeAlD
Tamoxifen—CYP19A1—lymph node—ovarian cancer	8.21e-05	0.00212	CbGeAlD
Tamoxifen—CYP3A5—vagina—ovarian cancer	8.2e-05	0.00211	CbGeAlD
Tamoxifen—CYP2B6—vagina—ovarian cancer	8.15e-05	0.0021	CbGeAlD
Tamoxifen—CYP2C8—testis—ovarian cancer	8.11e-05	0.00209	CbGeAlD
Tamoxifen—SIGMAR1—lymph node—ovarian cancer	8.07e-05	0.00208	CbGeAlD
Tamoxifen—ABCB1—embryo—ovarian cancer	7.95e-05	0.00205	CbGeAlD
Tamoxifen—ABCG2—testis—ovarian cancer	7.88e-05	0.00203	CbGeAlD
Tamoxifen—ABCC2—lymph node—ovarian cancer	7.84e-05	0.00202	CbGeAlD
Tamoxifen—CYP1B1—lymph node—ovarian cancer	7.68e-05	0.00198	CbGeAlD
Tamoxifen—CYP2B6—testis—ovarian cancer	7.27e-05	0.00187	CbGeAlD
Tamoxifen—ESR1—lymph node—ovarian cancer	7.14e-05	0.00184	CbGeAlD
Tamoxifen—Toremifene—ABCB1—ovarian cancer	7e-05	0.0698	CrCbGaD
Tamoxifen—CYP2E1—testis—ovarian cancer	6.83e-05	0.00176	CbGeAlD
Tamoxifen—CYP3A4—female reproductive system—ovarian cancer	6.81e-05	0.00175	CbGeAlD
Tamoxifen—CYP2D6—female reproductive system—ovarian cancer	6.7e-05	0.00173	CbGeAlD
Tamoxifen—ABCB1—epithelium—ovarian cancer	6.49e-05	0.00167	CbGeAlD
Tamoxifen—ABCB1—uterine cervix—ovarian cancer	6.43e-05	0.00166	CbGeAlD
Tamoxifen—ABCB1—decidua—ovarian cancer	6.13e-05	0.00158	CbGeAlD
Tamoxifen—CYP2D6—female gonad—ovarian cancer	6.09e-05	0.00157	CbGeAlD
Tamoxifen—Clomifene—ABCB1—ovarian cancer	6.05e-05	0.0604	CrCbGaD
Tamoxifen—ABCB1—endometrium—ovarian cancer	5.82e-05	0.0015	CbGeAlD
Tamoxifen—ABCG2—lymph node—ovarian cancer	5.72e-05	0.00147	CbGeAlD
Tamoxifen—CYP1A1—lymph node—ovarian cancer	5.43e-05	0.0014	CbGeAlD
Tamoxifen—CYP2D6—testis—ovarian cancer	5.41e-05	0.00139	CbGeAlD
Tamoxifen—ABCB1—gonad—ovarian cancer	5.39e-05	0.00139	CbGeAlD
Tamoxifen—ABCB1—uterus—ovarian cancer	5.36e-05	0.00138	CbGeAlD
Tamoxifen—ABCB1—female reproductive system—ovarian cancer	4.82e-05	0.00124	CbGeAlD
Tamoxifen—Hot flush—Doxorubicin—ovarian cancer	4.58e-05	0.000657	CcSEcCtD
Tamoxifen—Visual impairment—Docetaxel—ovarian cancer	4.58e-05	0.000656	CcSEcCtD
Tamoxifen—Dizziness—Topotecan—ovarian cancer	4.58e-05	0.000656	CcSEcCtD
Tamoxifen—ABCB1—bone marrow—ovarian cancer	4.55e-05	0.00117	CbGeAlD
Tamoxifen—Menopausal symptoms—Doxorubicin—ovarian cancer	4.54e-05	0.000651	CcSEcCtD
Tamoxifen—Anaemia—Paclitaxel—ovarian cancer	4.51e-05	0.000646	CcSEcCtD
Tamoxifen—Erythema multiforme—Docetaxel—ovarian cancer	4.49e-05	0.000644	CcSEcCtD
Tamoxifen—Dermatitis bullous—Doxorubicin—ovarian cancer	4.49e-05	0.000643	CcSEcCtD
Tamoxifen—Angioedema—Paclitaxel—ovarian cancer	4.46e-05	0.000639	CcSEcCtD
Tamoxifen—Flushing—Docetaxel—ovarian cancer	4.41e-05	0.000632	CcSEcCtD
Tamoxifen—Vomiting—Topotecan—ovarian cancer	4.4e-05	0.000631	CcSEcCtD
Tamoxifen—Mood swings—Epirubicin—ovarian cancer	4.39e-05	0.000629	CcSEcCtD
Tamoxifen—ABCB1—female gonad—ovarian cancer	4.38e-05	0.00113	CbGeAlD
Tamoxifen—Leukopenia—Paclitaxel—ovarian cancer	4.37e-05	0.000626	CcSEcCtD
Tamoxifen—Rash—Topotecan—ovarian cancer	4.36e-05	0.000625	CcSEcCtD
Tamoxifen—Hypersensitivity—Vinorelbine—ovarian cancer	4.36e-05	0.000625	CcSEcCtD
Tamoxifen—Dermatitis—Topotecan—ovarian cancer	4.36e-05	0.000625	CcSEcCtD
Tamoxifen—ABCB1—vagina—ovarian cancer	4.36e-05	0.00112	CbGeAlD
Tamoxifen—Blood creatinine increased—Epirubicin—ovarian cancer	4.34e-05	0.000622	CcSEcCtD
Tamoxifen—Headache—Topotecan—ovarian cancer	4.34e-05	0.000621	CcSEcCtD
Tamoxifen—Vomiting—Melphalan—ovarian cancer	4.31e-05	0.000618	CcSEcCtD
Tamoxifen—Osteoarthritis—Doxorubicin—ovarian cancer	4.29e-05	0.000614	CcSEcCtD
Tamoxifen—Liver function test abnormal—Epirubicin—ovarian cancer	4.28e-05	0.000613	CcSEcCtD
Tamoxifen—Rash—Melphalan—ovarian cancer	4.27e-05	0.000612	CcSEcCtD
Tamoxifen—Dermatitis—Melphalan—ovarian cancer	4.27e-05	0.000612	CcSEcCtD
Tamoxifen—Cough—Paclitaxel—ovarian cancer	4.26e-05	0.00061	CcSEcCtD
Tamoxifen—Asthenia—Vinorelbine—ovarian cancer	4.25e-05	0.000609	CcSEcCtD
Tamoxifen—Arrhythmia—Docetaxel—ovarian cancer	4.24e-05	0.000608	CcSEcCtD
Tamoxifen—Hypertension—Paclitaxel—ovarian cancer	4.21e-05	0.000604	CcSEcCtD
Tamoxifen—Alopecia—Docetaxel—ovarian cancer	4.2e-05	0.000602	CcSEcCtD
Tamoxifen—Pruritus—Vinorelbine—ovarian cancer	4.19e-05	0.0006	CcSEcCtD
Tamoxifen—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	4.17e-05	0.000598	CcSEcCtD
Tamoxifen—Chest pain—Paclitaxel—ovarian cancer	4.15e-05	0.000595	CcSEcCtD
Tamoxifen—Arthralgia—Paclitaxel—ovarian cancer	4.15e-05	0.000595	CcSEcCtD
Tamoxifen—Myalgia—Paclitaxel—ovarian cancer	4.15e-05	0.000595	CcSEcCtD
Tamoxifen—Anxiety—Paclitaxel—ovarian cancer	4.14e-05	0.000593	CcSEcCtD
Tamoxifen—Erythema—Docetaxel—ovarian cancer	4.14e-05	0.000593	CcSEcCtD
Tamoxifen—Nausea—Topotecan—ovarian cancer	4.11e-05	0.000589	CcSEcCtD
Tamoxifen—Discomfort—Paclitaxel—ovarian cancer	4.1e-05	0.000588	CcSEcCtD
Tamoxifen—Alanine aminotransferase increased—Epirubicin—ovarian cancer	4.09e-05	0.000586	CcSEcCtD
Tamoxifen—Dry mouth—Paclitaxel—ovarian cancer	4.06e-05	0.000582	CcSEcCtD
Tamoxifen—Mood swings—Doxorubicin—ovarian cancer	4.06e-05	0.000582	CcSEcCtD
Tamoxifen—Diarrhoea—Vinorelbine—ovarian cancer	4.05e-05	0.000581	CcSEcCtD
Tamoxifen—Dysgeusia—Docetaxel—ovarian cancer	4.05e-05	0.000581	CcSEcCtD
Tamoxifen—Nausea—Melphalan—ovarian cancer	4.03e-05	0.000577	CcSEcCtD
Tamoxifen—Blood creatinine increased—Doxorubicin—ovarian cancer	4.02e-05	0.000576	CcSEcCtD
Tamoxifen—Influenza—Epirubicin—ovarian cancer	4e-05	0.000574	CcSEcCtD
Tamoxifen—Dysphagia—Epirubicin—ovarian cancer	4e-05	0.000574	CcSEcCtD
Tamoxifen—Back pain—Docetaxel—ovarian cancer	4e-05	0.000573	CcSEcCtD
Tamoxifen—Oedema—Paclitaxel—ovarian cancer	3.98e-05	0.000571	CcSEcCtD
Tamoxifen—Muscle spasms—Docetaxel—ovarian cancer	3.98e-05	0.00057	CcSEcCtD
Tamoxifen—Liver function test abnormal—Doxorubicin—ovarian cancer	3.96e-05	0.000567	CcSEcCtD
Tamoxifen—Infection—Paclitaxel—ovarian cancer	3.96e-05	0.000567	CcSEcCtD
Tamoxifen—Pancreatitis—Epirubicin—ovarian cancer	3.93e-05	0.000563	CcSEcCtD
Tamoxifen—Dizziness—Vinorelbine—ovarian cancer	3.92e-05	0.000561	CcSEcCtD
Tamoxifen—Angina pectoris—Epirubicin—ovarian cancer	3.9e-05	0.000559	CcSEcCtD
Tamoxifen—Thrombocytopenia—Paclitaxel—ovarian cancer	3.9e-05	0.000559	CcSEcCtD
Tamoxifen—Loperamide—ABCB1—ovarian cancer	3.89e-05	0.0388	CrCbGaD
Tamoxifen—ABCB1—testis—ovarian cancer	3.89e-05	0.001	CbGeAlD
Tamoxifen—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	3.86e-05	0.000553	CcSEcCtD
Tamoxifen—Bronchitis—Epirubicin—ovarian cancer	3.85e-05	0.000552	CcSEcCtD
Tamoxifen—Hyperhidrosis—Paclitaxel—ovarian cancer	3.85e-05	0.000552	CcSEcCtD
Tamoxifen—Anaemia—Docetaxel—ovarian cancer	3.82e-05	0.000548	CcSEcCtD
Tamoxifen—Pancytopenia—Epirubicin—ovarian cancer	3.8e-05	0.000545	CcSEcCtD
Tamoxifen—Anorexia—Paclitaxel—ovarian cancer	3.8e-05	0.000544	CcSEcCtD
Tamoxifen—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	3.78e-05	0.000542	CcSEcCtD
Tamoxifen—Vomiting—Vinorelbine—ovarian cancer	3.76e-05	0.00054	CcSEcCtD
Tamoxifen—Neutropenia—Epirubicin—ovarian cancer	3.74e-05	0.000537	CcSEcCtD
Tamoxifen—Rash—Vinorelbine—ovarian cancer	3.73e-05	0.000535	CcSEcCtD
Tamoxifen—Dermatitis—Vinorelbine—ovarian cancer	3.73e-05	0.000535	CcSEcCtD
Tamoxifen—Headache—Vinorelbine—ovarian cancer	3.71e-05	0.000532	CcSEcCtD
Tamoxifen—Influenza—Doxorubicin—ovarian cancer	3.7e-05	0.000531	CcSEcCtD
Tamoxifen—Dysphagia—Doxorubicin—ovarian cancer	3.7e-05	0.000531	CcSEcCtD
Tamoxifen—Leukopenia—Docetaxel—ovarian cancer	3.7e-05	0.000531	CcSEcCtD
Tamoxifen—Weight increased—Epirubicin—ovarian cancer	3.64e-05	0.000522	CcSEcCtD
Tamoxifen—Pancreatitis—Doxorubicin—ovarian cancer	3.63e-05	0.000521	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	3.63e-05	0.00052	CcSEcCtD
Tamoxifen—Weight decreased—Epirubicin—ovarian cancer	3.62e-05	0.000519	CcSEcCtD
Tamoxifen—Cough—Docetaxel—ovarian cancer	3.61e-05	0.000517	CcSEcCtD
Tamoxifen—Angina pectoris—Doxorubicin—ovarian cancer	3.61e-05	0.000517	CcSEcCtD
Tamoxifen—Insomnia—Paclitaxel—ovarian cancer	3.6e-05	0.000516	CcSEcCtD
Tamoxifen—Pneumonia—Epirubicin—ovarian cancer	3.59e-05	0.000515	CcSEcCtD
Tamoxifen—Paraesthesia—Paclitaxel—ovarian cancer	3.58e-05	0.000513	CcSEcCtD
Tamoxifen—Hypertension—Docetaxel—ovarian cancer	3.57e-05	0.000512	CcSEcCtD
Tamoxifen—Bronchitis—Doxorubicin—ovarian cancer	3.56e-05	0.000511	CcSEcCtD
Tamoxifen—Dyspnoea—Paclitaxel—ovarian cancer	3.55e-05	0.000509	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	3.54e-05	0.000507	CcSEcCtD
Tamoxifen—Arthralgia—Docetaxel—ovarian cancer	3.52e-05	0.000505	CcSEcCtD
Tamoxifen—Myalgia—Docetaxel—ovarian cancer	3.52e-05	0.000505	CcSEcCtD
Tamoxifen—Chest pain—Docetaxel—ovarian cancer	3.52e-05	0.000505	CcSEcCtD
Tamoxifen—Pancytopenia—Doxorubicin—ovarian cancer	3.52e-05	0.000504	CcSEcCtD
Tamoxifen—Nausea—Vinorelbine—ovarian cancer	3.52e-05	0.000504	CcSEcCtD
Tamoxifen—Dyspepsia—Paclitaxel—ovarian cancer	3.51e-05	0.000502	CcSEcCtD
Tamoxifen—Urinary tract infection—Epirubicin—ovarian cancer	3.47e-05	0.000497	CcSEcCtD
Tamoxifen—Neutropenia—Doxorubicin—ovarian cancer	3.46e-05	0.000497	CcSEcCtD
Tamoxifen—Decreased appetite—Paclitaxel—ovarian cancer	3.46e-05	0.000496	CcSEcCtD
Tamoxifen—Dry mouth—Docetaxel—ovarian cancer	3.44e-05	0.000494	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Paclitaxel—ovarian cancer	3.44e-05	0.000493	CcSEcCtD
Tamoxifen—Fatigue—Paclitaxel—ovarian cancer	3.43e-05	0.000492	CcSEcCtD
Tamoxifen—Sweating—Epirubicin—ovarian cancer	3.42e-05	0.000491	CcSEcCtD
Tamoxifen—Constipation—Paclitaxel—ovarian cancer	3.41e-05	0.000488	CcSEcCtD
Tamoxifen—Pain—Paclitaxel—ovarian cancer	3.41e-05	0.000488	CcSEcCtD
Tamoxifen—Oedema—Docetaxel—ovarian cancer	3.38e-05	0.000484	CcSEcCtD
Tamoxifen—Weight increased—Doxorubicin—ovarian cancer	3.37e-05	0.000483	CcSEcCtD
Tamoxifen—Infection—Docetaxel—ovarian cancer	3.35e-05	0.000481	CcSEcCtD
Tamoxifen—Weight decreased—Doxorubicin—ovarian cancer	3.35e-05	0.00048	CcSEcCtD
Tamoxifen—Sinusitis—Epirubicin—ovarian cancer	3.35e-05	0.00048	CcSEcCtD
Tamoxifen—Pneumonia—Doxorubicin—ovarian cancer	3.32e-05	0.000476	CcSEcCtD
Tamoxifen—Thrombocytopenia—Docetaxel—ovarian cancer	3.31e-05	0.000474	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	3.28e-05	0.000469	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Paclitaxel—ovarian cancer	3.26e-05	0.000467	CcSEcCtD
Tamoxifen—Haemoglobin—Epirubicin—ovarian cancer	3.22e-05	0.000462	CcSEcCtD
Tamoxifen—Anorexia—Docetaxel—ovarian cancer	3.22e-05	0.000461	CcSEcCtD
Tamoxifen—Urinary tract infection—Doxorubicin—ovarian cancer	3.21e-05	0.00046	CcSEcCtD
Tamoxifen—Haemorrhage—Epirubicin—ovarian cancer	3.21e-05	0.000459	CcSEcCtD
Tamoxifen—Hepatitis—Epirubicin—ovarian cancer	3.21e-05	0.000459	CcSEcCtD
Tamoxifen—Hypoaesthesia—Epirubicin—ovarian cancer	3.19e-05	0.000457	CcSEcCtD
Tamoxifen—Pharyngitis—Epirubicin—ovarian cancer	3.18e-05	0.000456	CcSEcCtD
Tamoxifen—Sweating—Doxorubicin—ovarian cancer	3.17e-05	0.000454	CcSEcCtD
Tamoxifen—Urticaria—Paclitaxel—ovarian cancer	3.16e-05	0.000453	CcSEcCtD
Tamoxifen—Oedema peripheral—Epirubicin—ovarian cancer	3.16e-05	0.000452	CcSEcCtD
Tamoxifen—Abdominal pain—Paclitaxel—ovarian cancer	3.15e-05	0.000451	CcSEcCtD
Tamoxifen—Sinusitis—Doxorubicin—ovarian cancer	3.1e-05	0.000444	CcSEcCtD
Tamoxifen—Visual impairment—Epirubicin—ovarian cancer	3.09e-05	0.000443	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Docetaxel—ovarian cancer	3.08e-05	0.000441	CcSEcCtD
Tamoxifen—Insomnia—Docetaxel—ovarian cancer	3.05e-05	0.000438	CcSEcCtD
Tamoxifen—Paraesthesia—Docetaxel—ovarian cancer	3.03e-05	0.000434	CcSEcCtD
Tamoxifen—Erythema multiforme—Epirubicin—ovarian cancer	3.03e-05	0.000434	CcSEcCtD
Tamoxifen—Dyspnoea—Docetaxel—ovarian cancer	3.01e-05	0.000431	CcSEcCtD
Tamoxifen—Haemoglobin—Doxorubicin—ovarian cancer	2.98e-05	0.000427	CcSEcCtD
Tamoxifen—Flushing—Epirubicin—ovarian cancer	2.97e-05	0.000426	CcSEcCtD
Tamoxifen—Dyspepsia—Docetaxel—ovarian cancer	2.97e-05	0.000426	CcSEcCtD
Tamoxifen—Haemorrhage—Doxorubicin—ovarian cancer	2.97e-05	0.000425	CcSEcCtD
Tamoxifen—Hepatitis—Doxorubicin—ovarian cancer	2.97e-05	0.000425	CcSEcCtD
Tamoxifen—Hypoaesthesia—Doxorubicin—ovarian cancer	2.95e-05	0.000423	CcSEcCtD
Tamoxifen—Pharyngitis—Doxorubicin—ovarian cancer	2.94e-05	0.000422	CcSEcCtD
Tamoxifen—Decreased appetite—Docetaxel—ovarian cancer	2.93e-05	0.000421	CcSEcCtD
Tamoxifen—Hypersensitivity—Paclitaxel—ovarian cancer	2.93e-05	0.000421	CcSEcCtD
Tamoxifen—Oedema peripheral—Doxorubicin—ovarian cancer	2.92e-05	0.000419	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Docetaxel—ovarian cancer	2.91e-05	0.000418	CcSEcCtD
Tamoxifen—Fatigue—Docetaxel—ovarian cancer	2.91e-05	0.000417	CcSEcCtD
Tamoxifen—Pain—Docetaxel—ovarian cancer	2.89e-05	0.000414	CcSEcCtD
Tamoxifen—Constipation—Docetaxel—ovarian cancer	2.89e-05	0.000414	CcSEcCtD
Tamoxifen—Arrhythmia—Epirubicin—ovarian cancer	2.86e-05	0.00041	CcSEcCtD
Tamoxifen—Visual impairment—Doxorubicin—ovarian cancer	2.86e-05	0.00041	CcSEcCtD
Tamoxifen—Asthenia—Paclitaxel—ovarian cancer	2.86e-05	0.00041	CcSEcCtD
Tamoxifen—Alopecia—Epirubicin—ovarian cancer	2.83e-05	0.000406	CcSEcCtD
Tamoxifen—ABCB1—lymph node—ovarian cancer	2.82e-05	0.000726	CbGeAlD
Tamoxifen—Pruritus—Paclitaxel—ovarian cancer	2.82e-05	0.000404	CcSEcCtD
Tamoxifen—Erythema multiforme—Doxorubicin—ovarian cancer	2.8e-05	0.000402	CcSEcCtD
Tamoxifen—Erythema—Epirubicin—ovarian cancer	2.79e-05	0.0004	CcSEcCtD
Tamoxifen—Methadone—ABCB1—ovarian cancer	2.77e-05	0.0277	CrCbGaD
Tamoxifen—Gastrointestinal pain—Docetaxel—ovarian cancer	2.76e-05	0.000396	CcSEcCtD
Tamoxifen—Flushing—Doxorubicin—ovarian cancer	2.75e-05	0.000394	CcSEcCtD
Tamoxifen—Dysgeusia—Epirubicin—ovarian cancer	2.73e-05	0.000392	CcSEcCtD
Tamoxifen—Diarrhoea—Paclitaxel—ovarian cancer	2.73e-05	0.000391	CcSEcCtD
Tamoxifen—Back pain—Epirubicin—ovarian cancer	2.7e-05	0.000387	CcSEcCtD
Tamoxifen—Muscle spasms—Epirubicin—ovarian cancer	2.68e-05	0.000384	CcSEcCtD
Tamoxifen—Abdominal pain—Docetaxel—ovarian cancer	2.67e-05	0.000382	CcSEcCtD
Tamoxifen—Arrhythmia—Doxorubicin—ovarian cancer	2.65e-05	0.00038	CcSEcCtD
Tamoxifen—Dizziness—Paclitaxel—ovarian cancer	2.63e-05	0.000377	CcSEcCtD
Tamoxifen—Alopecia—Doxorubicin—ovarian cancer	2.62e-05	0.000376	CcSEcCtD
Tamoxifen—Erythema—Doxorubicin—ovarian cancer	2.58e-05	0.00037	CcSEcCtD
Tamoxifen—Anaemia—Epirubicin—ovarian cancer	2.58e-05	0.00037	CcSEcCtD
Tamoxifen—Vomiting—Paclitaxel—ovarian cancer	2.53e-05	0.000363	CcSEcCtD
Tamoxifen—Dysgeusia—Doxorubicin—ovarian cancer	2.53e-05	0.000362	CcSEcCtD
Tamoxifen—Rash—Paclitaxel—ovarian cancer	2.51e-05	0.00036	CcSEcCtD
Tamoxifen—Dermatitis—Paclitaxel—ovarian cancer	2.51e-05	0.00036	CcSEcCtD
Tamoxifen—Leukopenia—Epirubicin—ovarian cancer	2.5e-05	0.000358	CcSEcCtD
Tamoxifen—Back pain—Doxorubicin—ovarian cancer	2.5e-05	0.000358	CcSEcCtD
Tamoxifen—Headache—Paclitaxel—ovarian cancer	2.5e-05	0.000358	CcSEcCtD
Tamoxifen—Hypersensitivity—Docetaxel—ovarian cancer	2.49e-05	0.000356	CcSEcCtD
Tamoxifen—Muscle spasms—Doxorubicin—ovarian cancer	2.48e-05	0.000356	CcSEcCtD
Tamoxifen—Cough—Epirubicin—ovarian cancer	2.43e-05	0.000349	CcSEcCtD
Tamoxifen—Asthenia—Docetaxel—ovarian cancer	2.42e-05	0.000347	CcSEcCtD
Tamoxifen—Hypertension—Epirubicin—ovarian cancer	2.41e-05	0.000345	CcSEcCtD
Tamoxifen—Pruritus—Docetaxel—ovarian cancer	2.39e-05	0.000342	CcSEcCtD
Tamoxifen—Anaemia—Doxorubicin—ovarian cancer	2.39e-05	0.000342	CcSEcCtD
Tamoxifen—Chest pain—Epirubicin—ovarian cancer	2.38e-05	0.00034	CcSEcCtD
Tamoxifen—Arthralgia—Epirubicin—ovarian cancer	2.38e-05	0.00034	CcSEcCtD
Tamoxifen—Myalgia—Epirubicin—ovarian cancer	2.38e-05	0.00034	CcSEcCtD
Tamoxifen—Anxiety—Epirubicin—ovarian cancer	2.37e-05	0.000339	CcSEcCtD
Tamoxifen—Nausea—Paclitaxel—ovarian cancer	2.37e-05	0.000339	CcSEcCtD
Tamoxifen—Discomfort—Epirubicin—ovarian cancer	2.35e-05	0.000336	CcSEcCtD
Tamoxifen—Dry mouth—Epirubicin—ovarian cancer	2.32e-05	0.000333	CcSEcCtD
Tamoxifen—Leukopenia—Doxorubicin—ovarian cancer	2.31e-05	0.000331	CcSEcCtD
Tamoxifen—Diarrhoea—Docetaxel—ovarian cancer	2.31e-05	0.000331	CcSEcCtD
Tamoxifen—Oedema—Epirubicin—ovarian cancer	2.28e-05	0.000326	CcSEcCtD
Tamoxifen—Infection—Epirubicin—ovarian cancer	2.26e-05	0.000324	CcSEcCtD
Tamoxifen—Cough—Doxorubicin—ovarian cancer	2.25e-05	0.000323	CcSEcCtD
Tamoxifen—Dizziness—Docetaxel—ovarian cancer	2.23e-05	0.00032	CcSEcCtD
Tamoxifen—Thrombocytopenia—Epirubicin—ovarian cancer	2.23e-05	0.00032	CcSEcCtD
Tamoxifen—Hypertension—Doxorubicin—ovarian cancer	2.23e-05	0.000319	CcSEcCtD
Tamoxifen—Hyperhidrosis—Epirubicin—ovarian cancer	2.2e-05	0.000315	CcSEcCtD
Tamoxifen—Myalgia—Doxorubicin—ovarian cancer	2.2e-05	0.000315	CcSEcCtD
Tamoxifen—Chest pain—Doxorubicin—ovarian cancer	2.2e-05	0.000315	CcSEcCtD
Tamoxifen—Arthralgia—Doxorubicin—ovarian cancer	2.2e-05	0.000315	CcSEcCtD
Tamoxifen—Anxiety—Doxorubicin—ovarian cancer	2.19e-05	0.000314	CcSEcCtD
Tamoxifen—Discomfort—Doxorubicin—ovarian cancer	2.17e-05	0.000311	CcSEcCtD
Tamoxifen—Anorexia—Epirubicin—ovarian cancer	2.17e-05	0.000311	CcSEcCtD
Tamoxifen—Dry mouth—Doxorubicin—ovarian cancer	2.15e-05	0.000308	CcSEcCtD
Tamoxifen—Vomiting—Docetaxel—ovarian cancer	2.15e-05	0.000308	CcSEcCtD
Tamoxifen—Rash—Docetaxel—ovarian cancer	2.13e-05	0.000305	CcSEcCtD
Tamoxifen—Dermatitis—Docetaxel—ovarian cancer	2.13e-05	0.000305	CcSEcCtD
Tamoxifen—Headache—Docetaxel—ovarian cancer	2.11e-05	0.000303	CcSEcCtD
Tamoxifen—Oedema—Doxorubicin—ovarian cancer	2.11e-05	0.000302	CcSEcCtD
Tamoxifen—Infection—Doxorubicin—ovarian cancer	2.09e-05	0.0003	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Epirubicin—ovarian cancer	2.07e-05	0.000297	CcSEcCtD
Tamoxifen—Thrombocytopenia—Doxorubicin—ovarian cancer	2.06e-05	0.000296	CcSEcCtD
Tamoxifen—Insomnia—Epirubicin—ovarian cancer	2.06e-05	0.000295	CcSEcCtD
Tamoxifen—Paraesthesia—Epirubicin—ovarian cancer	2.04e-05	0.000293	CcSEcCtD
Tamoxifen—Hyperhidrosis—Doxorubicin—ovarian cancer	2.04e-05	0.000292	CcSEcCtD
Tamoxifen—Dyspnoea—Epirubicin—ovarian cancer	2.03e-05	0.000291	CcSEcCtD
Tamoxifen—Anorexia—Doxorubicin—ovarian cancer	2.01e-05	0.000288	CcSEcCtD
Tamoxifen—Nausea—Docetaxel—ovarian cancer	2.01e-05	0.000287	CcSEcCtD
Tamoxifen—Dyspepsia—Epirubicin—ovarian cancer	2e-05	0.000287	CcSEcCtD
Tamoxifen—Decreased appetite—Epirubicin—ovarian cancer	1.98e-05	0.000284	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Epirubicin—ovarian cancer	1.97e-05	0.000282	CcSEcCtD
Tamoxifen—Fatigue—Epirubicin—ovarian cancer	1.96e-05	0.000281	CcSEcCtD
Tamoxifen—Pain—Epirubicin—ovarian cancer	1.95e-05	0.000279	CcSEcCtD
Tamoxifen—Constipation—Epirubicin—ovarian cancer	1.95e-05	0.000279	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	1.92e-05	0.000275	CcSEcCtD
Tamoxifen—Insomnia—Doxorubicin—ovarian cancer	1.91e-05	0.000273	CcSEcCtD
Tamoxifen—Paraesthesia—Doxorubicin—ovarian cancer	1.89e-05	0.000271	CcSEcCtD
Tamoxifen—Dyspnoea—Doxorubicin—ovarian cancer	1.88e-05	0.000269	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Epirubicin—ovarian cancer	1.86e-05	0.000267	CcSEcCtD
Tamoxifen—Dyspepsia—Doxorubicin—ovarian cancer	1.85e-05	0.000266	CcSEcCtD
Tamoxifen—Decreased appetite—Doxorubicin—ovarian cancer	1.83e-05	0.000262	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Doxorubicin—ovarian cancer	1.82e-05	0.000261	CcSEcCtD
Tamoxifen—Fatigue—Doxorubicin—ovarian cancer	1.82e-05	0.00026	CcSEcCtD
Tamoxifen—Urticaria—Epirubicin—ovarian cancer	1.81e-05	0.000259	CcSEcCtD
Tamoxifen—Pain—Doxorubicin—ovarian cancer	1.8e-05	0.000258	CcSEcCtD
Tamoxifen—Constipation—Doxorubicin—ovarian cancer	1.8e-05	0.000258	CcSEcCtD
Tamoxifen—Abdominal pain—Epirubicin—ovarian cancer	1.8e-05	0.000258	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Doxorubicin—ovarian cancer	1.72e-05	0.000247	CcSEcCtD
Tamoxifen—Hypersensitivity—Epirubicin—ovarian cancer	1.68e-05	0.00024	CcSEcCtD
Tamoxifen—Urticaria—Doxorubicin—ovarian cancer	1.67e-05	0.00024	CcSEcCtD
Tamoxifen—Abdominal pain—Doxorubicin—ovarian cancer	1.67e-05	0.000239	CcSEcCtD
Tamoxifen—Asthenia—Epirubicin—ovarian cancer	1.63e-05	0.000234	CcSEcCtD
Tamoxifen—Pruritus—Epirubicin—ovarian cancer	1.61e-05	0.000231	CcSEcCtD
Tamoxifen—Diarrhoea—Epirubicin—ovarian cancer	1.56e-05	0.000223	CcSEcCtD
Tamoxifen—Hypersensitivity—Doxorubicin—ovarian cancer	1.55e-05	0.000222	CcSEcCtD
Tamoxifen—Asthenia—Doxorubicin—ovarian cancer	1.51e-05	0.000217	CcSEcCtD
Tamoxifen—Dizziness—Epirubicin—ovarian cancer	1.51e-05	0.000216	CcSEcCtD
Tamoxifen—Pruritus—Doxorubicin—ovarian cancer	1.49e-05	0.000214	CcSEcCtD
Tamoxifen—Vomiting—Epirubicin—ovarian cancer	1.45e-05	0.000207	CcSEcCtD
Tamoxifen—Diarrhoea—Doxorubicin—ovarian cancer	1.44e-05	0.000207	CcSEcCtD
Tamoxifen—Rash—Epirubicin—ovarian cancer	1.44e-05	0.000206	CcSEcCtD
Tamoxifen—Dermatitis—Epirubicin—ovarian cancer	1.43e-05	0.000206	CcSEcCtD
Tamoxifen—Headache—Epirubicin—ovarian cancer	1.43e-05	0.000204	CcSEcCtD
Tamoxifen—Dizziness—Doxorubicin—ovarian cancer	1.39e-05	0.0002	CcSEcCtD
Tamoxifen—Nausea—Epirubicin—ovarian cancer	1.35e-05	0.000194	CcSEcCtD
Tamoxifen—Vomiting—Doxorubicin—ovarian cancer	1.34e-05	0.000192	CcSEcCtD
Tamoxifen—Rash—Doxorubicin—ovarian cancer	1.33e-05	0.00019	CcSEcCtD
Tamoxifen—Dermatitis—Doxorubicin—ovarian cancer	1.33e-05	0.00019	CcSEcCtD
Tamoxifen—Headache—Doxorubicin—ovarian cancer	1.32e-05	0.000189	CcSEcCtD
Tamoxifen—Nausea—Doxorubicin—ovarian cancer	1.25e-05	0.000179	CcSEcCtD
Tamoxifen—ABCB1—Metabolism—YAP1—ovarian cancer	2.66e-06	7.81e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.66e-06	7.8e-05	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—AKT1—ovarian cancer	2.63e-06	7.74e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CYP1B1—ovarian cancer	2.62e-06	7.7e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CYP1B1—ovarian cancer	2.62e-06	7.69e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CAV1—ovarian cancer	2.62e-06	7.68e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.6e-06	7.62e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—SLC2A1—ovarian cancer	2.58e-06	7.57e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.52e-06	7.42e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—PIK3CB—ovarian cancer	2.51e-06	7.38e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—YAP1—ovarian cancer	2.51e-06	7.36e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.5e-06	7.34e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—FASN—ovarian cancer	2.49e-06	7.31e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—YAP1—ovarian cancer	2.48e-06	7.3e-05	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—PIK3CA—ovarian cancer	2.48e-06	7.28e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PIK3CG—ovarian cancer	2.47e-06	7.27e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CYP1B1—ovarian cancer	2.47e-06	7.26e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.46e-06	7.22e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—SLC5A5—ovarian cancer	2.45e-06	7.19e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.44e-06	7.17e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.44e-06	7.17e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.41e-06	7.06e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PIK3CG—ovarian cancer	2.38e-06	7e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CAV1—ovarian cancer	2.38e-06	6.99e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	2.37e-06	6.97e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.37e-06	6.96e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—SLC2A1—ovarian cancer	2.36e-06	6.94e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—CAV1—ovarian cancer	2.36e-06	6.93e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PPP2R1A—ovarian cancer	2.33e-06	6.83e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	2.32e-06	6.82e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.31e-06	6.8e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.31e-06	6.77e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CYP1B1—ovarian cancer	2.27e-06	6.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—FASN—ovarian cancer	2.22e-06	6.52e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—ABCB1—ovarian cancer	2.2e-06	6.47e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—TERT—ovarian cancer	2.2e-06	6.46e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	2.19e-06	6.44e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.18e-06	6.42e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.18e-06	6.41e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PIK3CD—ovarian cancer	2.18e-06	6.39e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—PTEN—ovarian cancer	2.17e-06	6.38e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PIK3CG—ovarian cancer	2.17e-06	6.37e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—FASN—ovarian cancer	2.17e-06	6.37e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—TYMS—ovarian cancer	2.17e-06	6.36e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CAV1—ovarian cancer	2.16e-06	6.35e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.16e-06	6.35e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—ABCB1—ovarian cancer	2.16e-06	6.34e-05	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—AKT1—ovarian cancer	2.16e-06	6.33e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—ABCB1—ovarian cancer	2.15e-06	6.33e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PIK3CG—ovarian cancer	2.15e-06	6.31e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—SLC5A5—ovarian cancer	2.13e-06	6.26e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—YAP1—ovarian cancer	2.12e-06	6.24e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—TYMS—ovarian cancer	2.12e-06	6.23e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—TYMS—ovarian cancer	2.12e-06	6.22e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.11e-06	6.2e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.1e-06	6.17e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PIK3CD—ovarian cancer	2.09e-06	6.15e-05	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—PIK3CA—ovarian cancer	2.08e-06	6.1e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.07e-06	6.07e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—SLC2A1—ovarian cancer	2.06e-06	6.05e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—FASN—ovarian cancer	2.04e-06	6e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—ABCB1—ovarian cancer	2.04e-06	5.98e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CAV1—ovarian cancer	2.03e-06	5.97e-05	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—AKT1—ovarian cancer	2.03e-06	5.95e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—FASN—ovarian cancer	2.03e-06	5.95e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.02e-06	5.94e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	2.01e-06	5.9e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.01e-06	5.9e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2e-06	5.87e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—TYMS—ovarian cancer	2e-06	5.87e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.99e-06	5.85e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.97e-06	5.8e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PIK3CG—ovarian cancer	1.97e-06	5.78e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.94e-06	5.7e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IL6ST—ovarian cancer	1.93e-06	5.66e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.92e-06	5.65e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PIK3CD—ovarian cancer	1.91e-06	5.6e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PIK3CB—ovarian cancer	1.9e-06	5.57e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PIK3CD—ovarian cancer	1.89e-06	5.55e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.88e-06	5.53e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—ABCB1—ovarian cancer	1.87e-06	5.48e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.86e-06	5.46e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	1.85e-06	5.44e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—APC—ovarian cancer	1.85e-06	5.44e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.85e-06	5.42e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.84e-06	5.42e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—TYMS—ovarian cancer	1.83e-06	5.38e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PIK3CB—ovarian cancer	1.83e-06	5.36e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.79e-06	5.27e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.79e-06	5.24e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.75e-06	5.14e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CAV1—ovarian cancer	1.74e-06	5.12e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PIK3CD—ovarian cancer	1.73e-06	5.09e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—FASN—ovarian cancer	1.73e-06	5.08e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CAV1—ovarian cancer	1.71e-06	5.02e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CAV1—ovarian cancer	1.71e-06	5.01e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.7e-06	5e-05	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—AKT1—ovarian cancer	1.7e-06	4.99e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.67e-06	4.89e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PIK3CB—ovarian cancer	1.66e-06	4.88e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.65e-06	4.85e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PIK3CB—ovarian cancer	1.65e-06	4.84e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.64e-06	4.83e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—YAP1—ovarian cancer	1.64e-06	4.81e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PTEN—ovarian cancer	1.64e-06	4.81e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—TYMS—ovarian cancer	1.64e-06	4.81e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.64e-06	4.8e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	1.63e-06	4.78e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.63e-06	4.78e-05	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—MAPK3—ovarian cancer	1.61e-06	4.73e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CAV1—ovarian cancer	1.61e-06	4.73e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.61e-06	4.73e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—TYMS—ovarian cancer	1.6e-06	4.69e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PIK3CG—ovarian cancer	1.59e-06	4.67e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PTEN—ovarian cancer	1.58e-06	4.63e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.58e-06	4.63e-05	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—MYC—ovarian cancer	1.57e-06	4.6e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PIK3CG—ovarian cancer	1.56e-06	4.57e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PIK3CG—ovarian cancer	1.55e-06	4.56e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.54e-06	4.52e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.53e-06	4.5e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—PIK3CA—ovarian cancer	1.53e-06	4.5e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.52e-06	4.46e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PIK3CB—ovarian cancer	1.51e-06	4.43e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—TYMS—ovarian cancer	1.5e-06	4.42e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—TYMS—ovarian cancer	1.49e-06	4.38e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CAV1—ovarian cancer	1.48e-06	4.34e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PIK3CG—ovarian cancer	1.47e-06	4.31e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—ERBB2—ovarian cancer	1.44e-06	4.22e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PTEN—ovarian cancer	1.44e-06	4.22e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PTEN—ovarian cancer	1.42e-06	4.18e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—MTOR—ovarian cancer	1.42e-06	4.17e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	1.42e-06	4.17e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.41e-06	4.14e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.4e-06	4.11e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PIK3CD—ovarian cancer	1.4e-06	4.1e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.39e-06	4.09e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PIK3CD—ovarian cancer	1.37e-06	4.02e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.37e-06	4.01e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CXCL8—ovarian cancer	1.36e-06	4.01e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.35e-06	3.95e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—FASN—ovarian cancer	1.34e-06	3.92e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	1.33e-06	3.91e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CAV1—ovarian cancer	1.32e-06	3.87e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.31e-06	3.86e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CASP3—ovarian cancer	1.31e-06	3.83e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PTEN—ovarian cancer	1.3e-06	3.83e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IL2—ovarian cancer	1.3e-06	3.83e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.3e-06	3.81e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PIK3CD—ovarian cancer	1.29e-06	3.79e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CAV1—ovarian cancer	1.29e-06	3.78e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—TYMS—ovarian cancer	1.27e-06	3.74e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CCND1—ovarian cancer	1.27e-06	3.73e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.27e-06	3.73e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.26e-06	3.7e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	1.26e-06	3.7e-05	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—AKT1—ovarian cancer	1.25e-06	3.68e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—MMP9—ovarian cancer	1.23e-06	3.62e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PTEN—ovarian cancer	1.23e-06	3.6e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.22e-06	3.58e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.22e-06	3.57e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CAV1—ovarian cancer	1.21e-06	3.56e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CAV1—ovarian cancer	1.2e-06	3.53e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.2e-06	3.53e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PIK3CB—ovarian cancer	1.19e-06	3.5e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.19e-06	3.5e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.18e-06	3.47e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.17e-06	3.44e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—PIK3CA—ovarian cancer	1.16e-06	3.39e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.15e-06	3.37e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PIK3CB—ovarian cancer	1.12e-06	3.3e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—PIK3CA—ovarian cancer	1.11e-06	3.27e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—VEGFA—ovarian cancer	1.11e-06	3.25e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.1e-06	3.24e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—STAT3—ovarian cancer	1.1e-06	3.22e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.09e-06	3.22e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—NRAS—ovarian cancer	1.09e-06	3.21e-05	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—AKT1—ovarian cancer	1.09e-06	3.19e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.08e-06	3.17e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.06e-06	3.1e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PTEN—ovarian cancer	1.05e-06	3.09e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—MAPK3—ovarian cancer	1.05e-06	3.08e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.03e-06	3.03e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PTEN—ovarian cancer	1.03e-06	3.03e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.03e-06	3.03e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PTEN—ovarian cancer	1.03e-06	3.02e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CAV1—ovarian cancer	1.03e-06	3.02e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—MYC—ovarian cancer	1.02e-06	2.99e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.01e-06	2.97e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—PIK3CA—ovarian cancer	1e-06	2.95e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—ABCB1—ovarian cancer	1e-06	2.94e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—MAPK1—ovarian cancer	9.97e-07	2.93e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—EGFR—ovarian cancer	9.97e-07	2.93e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—TYMS—ovarian cancer	9.84e-07	2.89e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.81e-07	2.88e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PTEN—ovarian cancer	9.72e-07	2.85e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PIK3CD—ovarian cancer	9.71e-07	2.85e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PIK3CD—ovarian cancer	9.63e-07	2.83e-05	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—AKT1—ovarian cancer	9.44e-07	2.77e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—KRAS—ovarian cancer	9.42e-07	2.77e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PIK3CG—ovarian cancer	9.36e-07	2.75e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PIK3CB—ovarian cancer	9.2e-07	2.7e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—PIK3CA—ovarian cancer	9.2e-07	2.7e-05	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—AKT1—ovarian cancer	9.09e-07	2.67e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PIK3CB—ovarian cancer	8.98e-07	2.64e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PTEN—ovarian cancer	8.91e-07	2.62e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	8.65e-07	2.54e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PIK3CB—ovarian cancer	8.46e-07	2.49e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PIK3CB—ovarian cancer	8.39e-07	2.46e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—TP53—ovarian cancer	8.37e-07	2.46e-05	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—AKT1—ovarian cancer	8.27e-07	2.43e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PIK3CD—ovarian cancer	8.23e-07	2.42e-05	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—AKT1—ovarian cancer	8.2e-07	2.41e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—HRAS—ovarian cancer	8.01e-07	2.35e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PTEN—ovarian cancer	7.95e-07	2.34e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CAV1—ovarian cancer	7.93e-07	2.33e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PTEN—ovarian cancer	7.76e-07	2.28e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—IL6—ovarian cancer	7.66e-07	2.25e-05	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—AKT1—ovarian cancer	7.52e-07	2.21e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—PIK3CA—ovarian cancer	7.42e-07	2.18e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PTEN—ovarian cancer	7.31e-07	2.15e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—PIK3CA—ovarian cancer	7.27e-07	2.14e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—PIK3CA—ovarian cancer	7.26e-07	2.13e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PTEN—ovarian cancer	7.25e-07	2.13e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PIK3CG—ovarian cancer	7.22e-07	2.12e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PIK3CB—ovarian cancer	7.17e-07	2.11e-05	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—AKT1—ovarian cancer	7.07e-07	2.08e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—PIK3CA—ovarian cancer	6.85e-07	2.01e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PIK3CD—ovarian cancer	6.35e-07	1.86e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—PIK3CA—ovarian cancer	6.28e-07	1.85e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PTEN—ovarian cancer	6.2e-07	1.82e-05	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—AKT1—ovarian cancer	6.06e-07	1.78e-05	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—AKT1—ovarian cancer	5.94e-07	1.74e-05	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—AKT1—ovarian cancer	5.93e-07	1.74e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—PIK3CA—ovarian cancer	5.61e-07	1.65e-05	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—AKT1—ovarian cancer	5.6e-07	1.64e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.53e-07	1.63e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—PIK3CA—ovarian cancer	5.47e-07	1.61e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.16e-07	1.52e-05	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—AKT1—ovarian cancer	5.13e-07	1.51e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—PIK3CA—ovarian cancer	5.11e-07	1.5e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PTEN—ovarian cancer	4.78e-07	1.4e-05	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—AKT1—ovarian cancer	4.58e-07	1.35e-05	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—AKT1—ovarian cancer	4.47e-07	1.31e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—PIK3CA—ovarian cancer	4.37e-07	1.28e-05	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—AKT1—ovarian cancer	4.21e-07	1.24e-05	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—AKT1—ovarian cancer	4.18e-07	1.23e-05	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—AKT1—ovarian cancer	3.57e-07	1.05e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.37e-07	9.91e-06	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—AKT1—ovarian cancer	2.76e-07	8.09e-06	CbGpPWpGaD
